Medimmune Limited

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Boston Pharmaceuticals, Inc.

Medlmmune Limited

Abbott Laboratories Corporation

Human Genome Sciences, Inc.

Syniverse Icx Corporation

Duke University

Partha S Chowdhury

Reena Varkey

Melissa Marie Damschroder

Bret Sellman

David Tice

Ira H Pastan

Nazzareno Dimasi

Changshou Gao

Ralph Raymond Minter

Charles K Stover

Xiaodong Xiao

Christine Tkaczyk

Sandrine Guillard

Steven Rust

Antonio Digiandomenico

Marlon Rebelatto

Krista Lynne Kinneer

Paul Warrener

Mladen Tomich

Lei Hua

Ryan Fleming

Philipp Steiner

Binyam Bezabeh

Vignesh Venkatraman

Zhan Xiao

Li Peng

Ronald Herbst

Godfrey Rainey

Stacey Drabic

Ping Tsui

Cuihua Gao

Qun Du

Peter Pavlik

Chew-shun Chang

Catherine Ettinger

Chien-Ying Chang

Rebecca Buonpane

Jodi Karnell

Laura Carter

Brian Michael Naiman

Herren Wu

Meina Liang

James F Young

Peter Kiener

Yen-Wah Lee

Vaheh Oganesyan

Robert E Hollingsworth

Martin Borrok, Iii

Koustubh Ranade

Yihong Yao

Katie Streicher

Ethan Grant

Lydia Greenlees

Nabendu Pore

Emil F Michelotti

Melissa Parker

Kevin P Baker

Amit Agarwal

Darell D Bigner

Venkat V Easwar

Susan E Brophy

Chirag C Bakshi

Vivian Albert

Richard Beers

Yariv Mazor

Bruce J Dille

Brett R Sellman

Jamese Johnson Hilliard

Gerard Davis

Andrew Pierce

Nicolette Jeanblanc

Saravanan Rajan

Michael Robert Kierny

Bret R Sellman

Christine J Tkaczyk

Reena M Varkey

Iii Martin J Borrok

David A Tice

Ralph Minter

Martin J Iii Borrok

This disclosure relates to combination therapies comprising anti-Psl and PcrV binding molecules and related compositions, for use in prevention and treatment ofinfection.

Combination therapies using anti-pseudomonas PSL and PCRV binding molecules

This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.

Binding molecules specific for ASCT2 and uses thereof

This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.

Antibodies specific for IL-21 and uses thereof

Antibodies and antigen binding fragments thereof directed against() surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treatingusing the antibodies and antigen binding fragments thereof are also provided.

[object Object]

Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.

Binding molecules specific for HER3 and uses thereof

This disclosure relates to polynucleotides encoding antibodies or antigen binding fragments thereof that bind toPcrV as well as vectors and host cells comprising the same.

Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv

The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.

Methods of using antibodies to determine periostin levels in a sample

Antibodies tosurface determinants

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of DPP-4 levels in samples obtained from human patients. The disclosure further provides novel anti-DPP-4 monoclonal antibodies that recognize human DPP-4, and assay kits comprising one or more of these antibodies.

Assay to detect human DPP-4

Growing community of inventors

Gaithersburg, MD, United States of America

Partha S Chowdhury